Edwards Lifesciences Corporation (EW) Stock

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is led by CEO Bernard J. Zovighian, employs 15,800 people, headquartered in Irvine, US, publicly traded since 2000.

Edwards Lifesciences Corporation (EW) stock trades at $89.07 with a market capitalization of $51.34B. The stock is valued at a price-to-earnings (P/E) ratio of 49.59, price-to-book of 4.68, price-to-sales of 7.63. Over the past 52 weeks the stock has ranged between $72.30 and $96.29, and currently trades 7.5% below its 52-week high.

On profitability, Edwards Lifesciences Corporation generates a return on equity (ROE) of 9.69%, return on capital employed of 14.80%, an operating margin of 26.96%, a net profit margin of 15.43%.

In its most recent fiscal year, Edwards Lifesciences Corporation reported annual revenue of $6.1B, net profit of $1.1B. Over the last 5 fiscal years, revenue grew at an average annual rate of 6.7%, and net profit grew at an average annual rate of 5.5%.

The balance sheet shows a debt-to-equity ratio of 0.07 (debt below half of shareholders' equity), a current ratio of 3.71, total assets of $13.7B, $2.9B in cash and equivalents.

EW has an average daily trading volume of 4,007,961 shares, a beta of 0.85.

Edwards Lifesciences Corporation by the numbers, 2016–2025

Between 2016 and 2025 Edwards Lifesciences Corporation reported revenue of $3.0B rising to $6.1B, a change of +104.7% across 10 years. Compounded, revenue has grown 6.7% a year over five years, 4.1% over three, 11.5% over the last twelve months. Net profit rose to $1.1B.

Operating margin went from 27.5% in 2016 to 27.0% in 2025, essentially unchanged. The most recent net margin is 15.43%. On a trailing twelve-month basis to Jun '26, revenue is $6.5B and net profit $1.0B.

Borrowings fell from $822.0M to $705.0M, cash from operations was $1.6B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 25.0% over five years, and was 10.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Edwards Lifesciences Corporation (EW) — frequently asked questions